Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of Oklahoma Health Sciences Center, ImmunoGen (United States), Wayne State University, The Barbara Ann Karmanos Cancer Institute, Harvard University, Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, The Ohio State University Wexner Medical Center, Fox Chase Cancer Center, GlaxoSmithKline (United Kingdom), The University of Texas at San Antonio Health Science Center
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2460145899